Related references
Note: Only part of the references are listed.A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Upasana Sunil Arvindam et al.
LEUKEMIA (2021)
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication
Nikolaus Jahn et al.
BLOOD ADVANCES (2020)
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
Peter Valent et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Targeting CLL-1 for acute myeloid leukemia therapy
Hongbing Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia
Tzu-yin Lin et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2019)
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis
Pieter Fokko van Loo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Peter Valent et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
Linde M. Morsink et al.
BLOOD REVIEWS (2019)
Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy
Marie Bill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker et al.
LEUKEMIA (2019)
Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology
Marie Bill et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia
Marie Toft-Petersen et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia
Ying-Ping Jiang et al.
BLOOD ADVANCES (2018)
An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Steven R. Leong et al.
BLOOD (2017)
Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia
Eduardo Laborda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1
Haruko Tashiro et al.
MOLECULAR THERAPY (2017)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Lowenberg et al.
BLOOD (2017)
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia
W. Zeijlemaker et al.
LEUKEMIA (2016)
CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses
Tim J. A. Hutten et al.
JOURNAL OF IMMUNOLOGY (2016)
Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered
Wendelien Zeijlemaker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity
Valerie R. Wiersma et al.
MABS (2015)
DNMT3A in haematological malignancies
Liubin Yang et al.
NATURE REVIEWS CANCER (2015)
Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia
Hua Lu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia
Monique Terwijn et al.
PLOS ONE (2014)
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Jan Kroenke et al.
BLOOD (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up
Hanne O. Larsen et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
Targeting C-type lectin-like molecule-1 for anti body-mediated immunotherapy in acute myeloid leukemia
Xiaoxian Zhao et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells
Anna van Rhenen et al.
BLOOD (2007)
Identification and characterization of a novel human Myeloid inhibitory c-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes
ASJ Marshall et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia
ABH Bakker et al.
CANCER RESEARCH (2004)
Share Paper
